Menu
- Home
+ - Publications
+
- Archives
+
- BCIQ
+
- Conferences
+
- eLearning
+
- Follow Us
Latest News
3:35 PM Aug 14, 2018
CVS to launch ICER-restricted formulary
CVS Health Corp. (NYSE:CVS) plans to offer a new formulary restricted to drugs deemed cost-effective by...
3:04 PM Aug 14, 2018
Management tracks: Cheng departing Gilead as CMO
Gilead Sciences Inc. (NASDAQ:GILD) said CMO Andrew Cheng will leave the company, effective Sept. 7, after...
2:05 PM Aug 14, 2018
Loncar's China biopharma fund to list on NASDAQ Wednesday
The Loncar China BioPharma ETF (NASDAQ:CHNA) is scheduled to begin trading on NASDAQ on Wednesday.
10:32 AM Aug 14, 2018
Motif's antibiotic gets Priority Review
Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) said FDA accepted and granted Priority Review to an NDA for...
7:02 AM Aug 14, 2018
Juvenescence, partners form anti-aging biotech
Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute...
4:04 PM Aug 13, 2018
Trump signs expanded CFIUS jurisdiction into law
President Donald Trump signed into law Monday the Foreign Investment Risk Review Modernization Act (...
2:03 PM Aug 13, 2018
Management tracks: FDA, Allergan
Patrick Frey will depart as chief of staff in FDA’s Office of New Drugs (OND) on Aug. 24 to become...
1:50 PM Aug 13, 2018
Mustang licenses immunodeficiency gene therapy from St. Jude
Mustang Bio Inc. (NASDAQ:MBIO) gained exclusive, worldwide rights to develop and commercialize an ex vivo...
1:46 PM Aug 13, 2018
Polygenic scores increase disease risk prediction
Two studies in Nature Genetics suggest that aggregating SNPs, instead of assessing single SNPs, to...
12:53 PM Aug 13, 2018
Amicus prices Galafold at $315k per year
Amicus Therapeutics Inc. (NASDAQ:FOLD) said Monday that it will price Galafold migalastat at $315,000 per...
12:22 PM Aug 13, 2018
Crossover investors join Orchard's syndicate in $150M series C
Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) raised $150 million in a series C round led...
11:22 AM Aug 13, 2018
NICE draft guidance recommends against Spinraza for SMA
U.K.’s NICE published draft guidance recommending against the use of Spinraza nusinersen from Biogen...
9:46 AM Aug 13, 2018
Priority Review for Stemline's blood cancer therapy
Stemline Therapeutics Inc. (NASDAQ:STML) said FDA accepted and granted Priority Review to its BLA for...
9:45 AM Aug 13, 2018
Delay for Regeneron’s 12-week Eylea regimen
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA issued a complete response letter to an sBLA for an...
3:03 AM Aug 13, 2018
MD Anderson launches neuroscience newco with $31M series A
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.)...
3:49 PM Aug 10, 2018
New approach could identify Ras-blocking small molecules
With an eye on historically undruggable cancer target Ras, a University of Oxford team and colleagues...
2:27 PM Aug 10, 2018
Astellas acquires ophthalmic company Quethera
Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.)...
1:35 PM Aug 10, 2018
Amicus' Galafold wins accelerated approval from FDA
FDA granted accelerated approval to Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD) to...
12:56 PM Aug 10, 2018
Management tracks: Oncopeptides, Merz
Cancer company Oncopeptides AB (SSE:ONCO) said CFO Birgitta Ståhl has stepped down. She is succeeded by...
11:37 AM Aug 10, 2018
RegenxBio raises $175.5M follow-on
RegenxBio Inc. (NASDAQ:RGNX) raised $175.5 million through the sale of 2.7 million shares at $65 in a...
About Biocentury
Contact
Support
Products & Solutions
Legal
- Follow Us
What is BioCentury?
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.